Cargando…

Analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas

OBJECTIVE: This study investigated the use and effectiveness of endoscopic transnasal, transsphenoidal surgery, a minimally invasive method for the treatment of macroadenomas and giant pituitary a denomas, in a medical setting. The surgical results of 429 patients who received neuroendoscopic treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Junyong, Zhang, Binbin, Shao, Dongqi, Ji, Shuxin, Li, Yu, Xie, Shan, Jiang, Zhiquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403245/
https://www.ncbi.nlm.nih.gov/pubmed/36034373
http://dx.doi.org/10.3389/fsurg.2022.956345
_version_ 1784773330864177152
author Wu, Junyong
Zhang, Binbin
Shao, Dongqi
Ji, Shuxin
Li, Yu
Xie, Shan
Jiang, Zhiquan
author_facet Wu, Junyong
Zhang, Binbin
Shao, Dongqi
Ji, Shuxin
Li, Yu
Xie, Shan
Jiang, Zhiquan
author_sort Wu, Junyong
collection PubMed
description OBJECTIVE: This study investigated the use and effectiveness of endoscopic transnasal, transsphenoidal surgery, a minimally invasive method for the treatment of macroadenomas and giant pituitary a denomas, in a medical setting. The surgical results of 429 patients who received neuroendoscopic treatment of macroadenomas or giant pituitary adenomas were evaluated, and the experiences and lessons learned from treatment complications were assessed. PATIENTS AND METHODS: From January 2012 to December 2021, 429 patients with macroadenomas or giant pituitary adenomas, including 60 patients with giant adenomas (diameter ≥4 cm) and 369 patients with macroadenomas (diameter 1–4 cm), received a 3D head CT, a MRI with contrast enhancement, and an endocrinology examination prior to surgery. Preoperative clinical and radiological features, visual measurements, hormone levels, length of stay, length of surgery, postoperative stay, visual and hormone outcomes, resection range, complication and recurrence rates, and routine patient information were recorded. The patients were followed up for 6–72 months (median = 40 months). RESULTS: Of 429 patients with macroadenomas or giant pituitary adenomas who received neuroendoscopic treatment, 348 (81.12%) had gross-total resections (GTR), 53 (12.35%) had near-total resections (NTR), and 28 (6.53%) had subtotal resections. There were 138 cases of post-operative diabetes insipidus (32.17%), including 7 cases of permanent diabetes insipidus (1.63%), 16 cases of nasal hemorrhage (3.73%), 39 cases of intraoperative cerebrospinal fluid leakage (9.09%), 4 cases of intracranial infection (0.9%), 16 cases of hypophysis (3.7%), and 15 cases of anosmia (3.50%). The clinical symptoms and endocrinology indices of the patients improved after surgery, and all patients were discharged 5–18 days (8.36 ± 2.65) postop. CONCLUSION: Neuroendoscopy is a safe operation with a short recovery period and hospital stay and is thus an effective method to treat macroadenomas and giant pituitary adenomas. Preoperative evaluation and prediction can help to accurately address possible intraoperative situations and improve GTR.
format Online
Article
Text
id pubmed-9403245
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94032452022-08-26 Analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas Wu, Junyong Zhang, Binbin Shao, Dongqi Ji, Shuxin Li, Yu Xie, Shan Jiang, Zhiquan Front Surg Surgery OBJECTIVE: This study investigated the use and effectiveness of endoscopic transnasal, transsphenoidal surgery, a minimally invasive method for the treatment of macroadenomas and giant pituitary a denomas, in a medical setting. The surgical results of 429 patients who received neuroendoscopic treatment of macroadenomas or giant pituitary adenomas were evaluated, and the experiences and lessons learned from treatment complications were assessed. PATIENTS AND METHODS: From January 2012 to December 2021, 429 patients with macroadenomas or giant pituitary adenomas, including 60 patients with giant adenomas (diameter ≥4 cm) and 369 patients with macroadenomas (diameter 1–4 cm), received a 3D head CT, a MRI with contrast enhancement, and an endocrinology examination prior to surgery. Preoperative clinical and radiological features, visual measurements, hormone levels, length of stay, length of surgery, postoperative stay, visual and hormone outcomes, resection range, complication and recurrence rates, and routine patient information were recorded. The patients were followed up for 6–72 months (median = 40 months). RESULTS: Of 429 patients with macroadenomas or giant pituitary adenomas who received neuroendoscopic treatment, 348 (81.12%) had gross-total resections (GTR), 53 (12.35%) had near-total resections (NTR), and 28 (6.53%) had subtotal resections. There were 138 cases of post-operative diabetes insipidus (32.17%), including 7 cases of permanent diabetes insipidus (1.63%), 16 cases of nasal hemorrhage (3.73%), 39 cases of intraoperative cerebrospinal fluid leakage (9.09%), 4 cases of intracranial infection (0.9%), 16 cases of hypophysis (3.7%), and 15 cases of anosmia (3.50%). The clinical symptoms and endocrinology indices of the patients improved after surgery, and all patients were discharged 5–18 days (8.36 ± 2.65) postop. CONCLUSION: Neuroendoscopy is a safe operation with a short recovery period and hospital stay and is thus an effective method to treat macroadenomas and giant pituitary adenomas. Preoperative evaluation and prediction can help to accurately address possible intraoperative situations and improve GTR. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9403245/ /pubmed/36034373 http://dx.doi.org/10.3389/fsurg.2022.956345 Text en © 2022 Wu, Zhang, Shao, Ji, Li, Xie and Jiang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Surgery
Wu, Junyong
Zhang, Binbin
Shao, Dongqi
Ji, Shuxin
Li, Yu
Xie, Shan
Jiang, Zhiquan
Analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas
title Analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas
title_full Analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas
title_fullStr Analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas
title_full_unstemmed Analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas
title_short Analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas
title_sort analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403245/
https://www.ncbi.nlm.nih.gov/pubmed/36034373
http://dx.doi.org/10.3389/fsurg.2022.956345
work_keys_str_mv AT wujunyong analysisofneuroendoscopyforthetreatmentofmacroadenomasandgiantpituitaryadenomas
AT zhangbinbin analysisofneuroendoscopyforthetreatmentofmacroadenomasandgiantpituitaryadenomas
AT shaodongqi analysisofneuroendoscopyforthetreatmentofmacroadenomasandgiantpituitaryadenomas
AT jishuxin analysisofneuroendoscopyforthetreatmentofmacroadenomasandgiantpituitaryadenomas
AT liyu analysisofneuroendoscopyforthetreatmentofmacroadenomasandgiantpituitaryadenomas
AT xieshan analysisofneuroendoscopyforthetreatmentofmacroadenomasandgiantpituitaryadenomas
AT jiangzhiquan analysisofneuroendoscopyforthetreatmentofmacroadenomasandgiantpituitaryadenomas